Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Idorsia Ltd
  6. News
  7. Übersicht
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Bericht
verzögerte Kurse. Verzögert Swiss Exchange - 02.12. 17:30:35
16.69 CHF   +0.91%
29.11.Morning Briefing - Markt Schweiz
AW
18.11.Aktien Schweiz Vorbörse: SMI trotz Inflationssorgen auf Rekordniveau
AW
01.11.Aktien Schweiz Schluss: SMI schliesst deutlich im Plus - CS Gewinner
AW
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen

GlobeNewswire/Johnson & Johnson partially converts its convertible loan

27.10.2021 | 19:04

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland -- October 27, 2021

Idorsia Ltd (SIX: IDIA) today announced that Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, notified Idorsia that it will convert a second tranche of the remaining principal amount of CHF 445 million convertible loan, such that CHF 110 million will be converted into 9.6 million shares of Idorsia.

As a result of the conversion, Idorsia will issue 9'581'882 new shares and Idorsia share capital will increase from CHF 8'364'748.55 to CHF 8'843'842.65, divided into 176'876'853 Idorsia shares.

As a result of conversion of the second tranche of the convertible loan, Cilag Holding AG will hold 5.7% of Idorsia's issued share capital. Following conversion, the remaining principal amount of the convertible loan will be CHF 335 million, convertible into 29.1 million shares of Idorsia.

Notes to the editor

About the convertible loan

On June 15, 2017, Cilag Holding AG ("Cilag") provided a loan of CHF 580 m to Idorsia, which was convertible into ordinary shares of Idorsia up to an aggregate of 32% of the share capital at the time that the loan was provided. The loan does not carry interest, has a term of 10 years and matures on June 15, 2027.

On June 19, 2017, a first tranche of the convertible loan of CHF 135 m was mandatorily converted and Cilag acquired 11,793,220 of the shares of Idorsia. These shares were sold by Cilag in a secondary offering on July 8, 2020.

About Idorsia

Idorsia Ltd is reaching out for more -- We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland -- a European biotech-hub -- Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet -- the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,000 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 58 844 10 10

investor.relations@idorsia.com -- media.relations@idorsia.com -- www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Anhang

   -- Medienmitteilung PDF 
      https://ml-eu.globenewswire.com/Resource/Download/fd1c361e-0ed1-4a73-805b-d12a83b733c9 
 
 
 

(END) Dow Jones Newswires

October 27, 2021 13:03 ET (17:03 GMT)

Alle Nachrichten zu IDORSIA LTD
29.11.Morning Briefing - Markt Schweiz
AW
18.11.Aktien Schweiz Vorbörse: SMI trotz Inflationssorgen auf Rekordniveau
AW
01.11.Aktien Schweiz Schluss: SMI schliesst deutlich im Plus - CS Gewinner
AW
01.11.Aktien Schweiz: SMI setzt Aufwärtstrend fort - CS gesucht
AW
01.11.Aktien Schweiz Eröffnung: SMI setzt Aufwärtstrend fort
AW
01.11.Idorsia-Aktien nach positiven News zu Cenerimod gesucht
AW
01.11.Morning Briefing - Markt Schweiz
AW
01.11.Aktien Schweiz Vorbörse: Dank positiven Auslandsvorgaben höher erwartet
AW
01.11.Idorsia plant Phase-III-Studie mit Cenerimod bei Bindegewebserkrankung Lupus
AW
01.11.Idorsia setzt Studie zur Behandlung der Lupus-Krankheit im Spätstadium fort
MT
Weitere Nachrichten und Newsletter
News auf Englisch zu IDORSIA LTD
01.11.Idorsia to Proceed With Late-Stage Study of Lupus Disease Treatment
MT
01.11.Idorsia to advance cenerimod into Phase 3 development for treatment of patients with sy..
AQ
01.11.Idorsia Ltd to Advance Cenerimod into Phase 3 Development for Treatment of Patients wit..
CI
28.10.Johnson & Johnson Unit To Partially Convert Loan To Idorsia
MT
27.10.Johnson & Johnson partially converts its convertible loan
AQ
27.10.Idorsia Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
26.10.IDORSIA : Financial Report Nine-Month 2021
PU
26.10.IDORSIA : Q3 Loss Widens As Operating Expenses Grow
MT
26.10.IDORSIA : announces financial results for the third quarter 2021 – company progressi..
AQ
14.10.ANALYST RECOMMENDATIONS : Asos, Avis Budget, Meritage Homes, Kansas City Southern, UPS...
Weitere Nachrichten und Newsletter auf Englisch
Analystenempfehlungen zu IDORSIA LTD
Mehr Empfehlungen
Finanzkennziffern
Umsatz 2021 37,8 Mio 41,0 Mio -
Nettoergebnis 2021 -606 Mio -658 Mio -
Nettoverschuldung 2021 558 Mio 606 Mio -
KGV 2021 -4,53x
Dividendenrendite 2021 -
Marktkapitalisierung 2 953 Mio 3 211 Mio -
Marktkap. / Umsatz 2021 93,0x
Marktkap. / Umsatz 2022 34,7x
Mitarbeiterzahl 650
Streubesitz 65,6%
Chart IDORSIA LTD
Dauer : Zeitraum :
Idorsia Ltd : Chartanalyse Idorsia Ltd | MarketScreener
Vollbild-Chart
Chartanalyse-Trends IDORSIA LTD
KurzfristigMittelfristigLangfristig
TrendsFallendFallendFallend
Ergebnisentwicklung
Analystenschätzung
Verkaufen
Kaufen
Durchschnittl. Empfehlung AUFSTOCKEN
Anzahl Analysten 11
Letzter Schlusskurs 16,69 CHF
Mittleres Kursziel 26,89 CHF
Abstand / Durchschnittliches Kursziel 61,1%
Verlauf des Gewinns je Aktie
Vorstände und Aufsichtsräte
Jean-Paul Clozel Chief Executive Officer & Director
André C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Branche und Wettbewerber
01.01.Wert (M$)
IDORSIA LTD-35.19%3 182
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122